Summary of Purpose
Background: Clopidogrel, an antiplatelet prodrug, is widely used for prevention of the recurrent cardiovascular events. CYP2C19 is one of the crucial enzymes for the activation of clopidogrel. Recent studies, mostly done in cardiovascular patients, showed association of the CYP2C19 genotypes with recurrent cardiovascular events. However, prospective data on the impact of the genetic variants in stroke...Read More →
The following dates are available for this trial. Trial information last updated on 17 March 2016.
|1 Oct 2009||9 Mar 2016||1 Apr 2014||1 Oct 2015||1 Mar 2016||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Observation: Cohort
- Perspective: Prospective
- Sampling: Probability Sample